Targeted Oncology™ To Launch Virtual Tumor Board

Expert oncologists will discuss chronic lymphocytic leukemia

Targeted Oncology™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 24. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This first one will focus on chronic lymphocytic leukemia (CLL).

"We are thrilled to introduce this educational platform for community-based oncologists," said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of Targeted Oncology™. "Through this initiative, we look forward to empowering oncologists by providing them with the latest updates from their specific field of practice."

The Virtual Tumor Board will feature multiple experts that will provide an in-depth analysis on CLL diagnosis, biomarker testing and therapeutic approaches from a collaborative medical setting. Together, these experts will provide a focused look at multiple case sets from a treatment team perspective to further educate community-based oncologists in this comprehensive series of practice-changing insights.

Key opinion leaders for this virtual tumor board are:

• Matthew Davids, M.D., MMSc., associate director, Center for Chronic Lymphocytic Leukemia, physician, Dara-Farber Cancer Center, assistant professor of medicine, Harvard Medical School
• William Wierda, M.D., Ph.D., D.B. Lane Cancer Research Distinguished professor, department of leukemia, division of cancer medicine, executive medical director, professor, department of leukemia, division of cancer medicine, section chief – chronic lymphocytic leukemia, department of leukemia, division of cancer medicine, center medical director, department of leukemia, division of cancer medicine, The University of Texas MD, Anderson Cancer Center
• Nitin Jain, M.D., assistant professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center
• Adam Bagg, M.D., professor, department of pathology and laboratory medicine, Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine

For more information and to view the virtual tumor board, visit http://www.targetedonc.com/.

About Targeted Oncology^™

TargetedOnc.com provides the latest news and insight on next-generation therapeutics and their molecular targets for practicing oncologists. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying up-to-date with the future of cancer therapeutics. As such, TargetedOnc strives to provide the latest information on breaking news and updates on the burgeoning field. By partnering with leading oncology networks such as the Community Oncology Alliance, Association of Community Cancer Centers and Society for Immunotherapy of Cancer, TargetedOnc focuses on the next stage of cancer development and on cutting-edge therapies and their biological targets. Content is organized by tumor type, news and conference coverage.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180419006299/en/